Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Longeveron Inc
LGVN
Healthcare
Biotechnology
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy...
adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:LGVN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 18, 2024 4:49pm
New Press Release - Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the closing of its...
read article.
(232)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 17, 2024 6:00pm
Longeveron® to Present at the Virtual Life Sciences Inv
News; $LGVN Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage
...more
QMET has 11 claims and 633 hectares Property in Ville-Marie, Quebec Hydrogen Camp
posted Nov 25, 2024 9:00am by
Q Precious & Battery Metals Corp.
-
|
The Company is pleased to discover that their Lorrain claims are now within the new and exciting exploration for hydrogen in the Ville-Marie, Lorrainville and Béarn region of Quebec. The region has undergone a claim staking rush following the ...read more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 17, 2024 9:19am
LGVN.....Guess what....u've all been had.... Again!
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds 2024-06-17 05:39 ET - News Release MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 13, 2024 9:11am
LGVN.....early a.m runner yesterday on back to back NR's
Big volume & price action this a.m ....22 million shs & trading at $2.45 I'd say some of the warrants are being exercised at $2.35 Could still run....but ...... Stops save portfolios
...more
(232)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 12, 2024 11:45am
Presenting on the Emerging Growth Conference 72 Day 2 on Jun
NEWS: $LGVN Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now | BenzingaMIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media
...more
(232)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 12, 2024 11:30am
Presenting on the Emerging Growth Conference 72 Day 2 on Jun
JUST IN: $LGVN Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register NowMIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 14, 2024 4:05pm
New Press Release - Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
Phase 2b clinical trial evaluating Lomecel-BTM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-BTM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer’s Association...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 10, 2024 4:05pm
New Press Release - Longeveron Announces Board of Directors Planned Transitions
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board Dr. Roger Hajjar, former head of R&D at Ring Therapeutics, has been nominated as a candidate for the Board, subject to election at the Company’s Annual...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 02, 2024 8:03am
New Press Release - Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 25, 2024 4:05pm
New Press Release - Longeveron to Present at the Planet MicroCap Showcase
MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024. Details for the Company’s presentation:Date...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Apr 19, 2024 8:19am
RE:LGVN.....ahhhh isn't that nice of the CEO to give the .....
What did I tell you on April 08th ???? That was "tomorrows News in advance" !!!!! Here is todays news....... Longeveron Raises a Total of $11.4 Million in Gross Proceeds from
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 18, 2024 4:05pm
New Press Release - Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
read article.
(232)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 17, 2024 6:00pm
New Study Shows Social Isolation, Frailty Worsen Health Risk
Just In: $LGVN New Study Shows Social Isolation, Frailty Worsen Health Risks for Aging PeopleA recently published review has found that social vulnerability and frailty worsen as individuals age. When
...more
(232)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 17, 2024 5:45pm
Longeveron Announces Exercise of Warrants for $6.2 Million G
JUST IN: $LGVN Longeveron Announces Exercise of Warrants for $6.2 Million Gross ProceedsMIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 17, 2024 8:00am
New Press Release - Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
MIAMI, April 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income